Ming Li

Dr. Ming Li

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
TLTing Li
Ting Li
SJShuhui Jiang
Shuhui Jiang
YZYing Zhang
Ying Zhang
JLJie Luo
Jie Luo
Ming LiMing Li
Ming Li
Huabing ChenHuabing Chen
Huabing Chen
The survival of malignant tumors is highly dependent on their intrinsic self-defense pathways such as heat shock protein (HSP) during cancer therapy. However, precisely dismantling self-defenses to amplify antitumor potency remains unexplored. Herein, we demonstrate that nanoparticle-mediated transient receptor potential vanilloid member 1 (TRPV1) channel blockade potentiates thermo-immunotherapy via suppressing heat shock factor 1 (HSF1)-mediated dual self-defense pathways. TRPV1 blockade inhibits hyperthermia-induced calcium influx and subsequent nuclear translocation of HSF1, which selectively suppresses stressfully overexpressed HSP70 for enhancing thermotherapeutic efficacy against a variety of primary, metastatic and recurrent tumor models. Particularly, the suppression of HSF1 translocation further restrains the transforming growth factor β (TGFβ) pathway to degrade the tumor stroma, which improves the infiltration of antitumor therapeutics (e.g. anti-PD-L1 antibody) and immune cells into highly fibrotic and immunosuppressive pancreatic cancers. As a result, TRPV1 blockade retrieves thermo-immunotherapy with tumor-eradicable and immune memory effects. The nanoparticle-mediated TRPV1 blockade represents as an effective approach to dismantle self-defenses for potent cancer therapy.

26 December 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Ming LiMing Li
Ming Li
SYShiyao Yin
Shiyao Yin
安徐安安 徐
安安 徐
LKLiyuan Kang
Liyuan Kang
ZMZiqian Ma
Ziqian Ma
YTYongan Tang
Yongan Tang
Oral squamous cell carcinoma (OSCC) contributes to more than 90% of all oral malignancies, yet the performance of traditional treatments is impeded by limited therapeutic effects and substantial side effects. In this work, we report a combinational treatment strategy based on tumor exosome-based nanoparticles co-formulating a photosensitizer (Indocyanine green) and a tyrosine kinase inhibitor (Gefitinib) (IG@EXOs) for boosting antitumor efficiency against OSCC through synergistic phototherapy-molecular targeted therapy. The IG@EXOs generate distinct photothermal/photodynamic effects through enhanced photothermal conversion efficiency and ROS generation, respectively. In vivo, the IG@EXOs efficiently accumulate in the tumor and penetrate deeply to the center of the tumor due to passive and homologous targeting. The phototherapy effects of IG@EXOs not only directly induce potent cancer cell damage but also promote the release and cytoplasmic translocation of Gefitinib for achieving significant inhibition of cell proliferation and tumor angiogenesis, eventually resulting in efficient tumor ablation and lymphatic metastasis inhibition through the synergistic phototherapy-molecular targeted therapy. We envision that the encouraging performances of IG@EXOs against cancer pave a new avenue for their future application in clinical OSCC treatment.

31 October 2022 in Acta Biomaterialia
Verified
Journal Article
Closed access
Ming LiMing Li
Ming Li
YWYuan Wang
Yuan Wang
TLTing Li
Ting Li
JZJuan Zhang
Juan Zhang
XWXue Wang
Xue Wang
HKHengte Ke
Hengte Ke

15 January 2025 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
QLQian Liu
Qian Liu
DJDandan Jiang
Dandan Jiang
SZShasha Zhang
Shasha Zhang
YRYi Ru
Yi Ru
JLJing Li
Jing Li
BLBiao liu
Biao liu

19 August 2025 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
SYShiyao Yin
Shiyao Yin
QLQian Liu
Qian Liu
BLBiao liu
Biao liu
Ming LiMing Li
Ming Li
MFMingyue Fan
Mingyue Fan
We developed photoactivatable Flt3L-EVs for targeted tumor therapy, ECM remodeling, and immune activation, enabling precise spatiotemporal immunotherapy with enhanced specificity.